KMDA +3% in pre-mkt following earlier PR: Kamada Announces a Three-Year $50M Sales Agreement to Supply Plasma to a Leading Biopharmaceutical
KMDA +3% in pre-mkt following earlier PR: Kamada Announces a Three-Year $50M Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies Through Texas Centers, Commercial Sales Starting Q4 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.